Skip to content

Preventing recurrent *idiopathic* acute pancreatitis through laparoscopic cholecystectomy (PICUS-2): a multicenter randomized trial

Preventing recurrent *idiopathic* acute pancreatitis through laparoscopic cholecystectomy (PICUS-2): a multicenter randomized trial - PICUS-2

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
NL-OMON
Registry ID
NL-OMON53591
Enrollment
220
Registered
2023-07-20
Start date
2024-01-19
Completion date
Unknown
Last updated
2026-01-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

idiopathic pancreatitis inflammation of the pancreas with an unknown origin

Interventions

The intervention of this study is a laparoscopic cholecystectomy performed within four weeks of the first episode of idiopathic acute pancreatitis or during initial admission.

Sponsors

Amsterdam UMC
Lead Sponsor

Eligibility

Age
18 Years to 99 Years

Inclusion criteria

Inclusion criteria: At least 18 years oldEligible for early cholecystectomyFull required diagnostic work-up of patient has been performed, including EUSFirst, second or third episode of IAP, in which at least one episode characterized by a negative EUS result has been reportedInformed consent for participation was obtained 

Exclusion criteria

Exclusion criteria: 1. Patients with more than 3 episodes of idiopathic acute pancreatitis 2. Diagnosis of chronic pancreatitis 3. Patients with a pancreatic malignancy 4. Patients who have received a laparoscopic cholecystectomy prior to PICUS-2 5. Patients in whom a known etiology is found during diagnostic work-up 6. Patients in whom complete diagnostic work-up by EUS is not possible (eg.  Roux-en-y bypass)

Design outcomes

Primary

MeasureTime frame
The primary outcome measure for this trial is a confirmed recurrent acute pancreatitis (irrespective of the aetiology of recurrent pancreatitis) within one year from the date of randomization

Secondary

MeasureTime frame
The secondary outcome measures for this trial are - Readmission for one or more of the following reasons: Recurrent pancreatitis; Cholecystitis; Cholangitis; Obstructive choledocholithiasis needing endoscopic retrograde cholangiopancreatography; Gallstone colic. - Complications of LC: Bile duct injury and bleeding; Requiring the need for additional surgical endoscopic, or radiological intervention; infection; Other complications such as pneumonia, bacteremia, and new-onset organ failure. - Number and severity of recurrent episodes of pancreatitis - Quality of life (QALY) - Costs (hospital and societal) - Cost-effectiveness

Countries

China, Germany, Hungary, Italy, Netherlands, Norway, Spain, Sweden

Contacts

Public ContactR.B. Schwarz

Amsterdam UMC

r.schwarz@amsterdamumc.nl+31631144931

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)